Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
by
Sengupta, Medha
, Henderson, Michael X.
, Lee, Virginia M. Y.
, Trojanowski, John Q.
in
Aggregation
/ Alzheimer Disease - genetics
/ Alzheimer Disease - pathology
/ Alzheimer's disease
/ Amyloid β
/ Analysis
/ Antibodies
/ Biomedical and Life Sciences
/ Biomedicine
/ Brain - pathology
/ Clinical trials
/ Comorbidity
/ G2019S
/ Genetic aspects
/ Heterozygote
/ Humans
/ Leucine-rich repeat kinase 2
/ Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - genetics
/ Medical research
/ Mutation - genetics
/ Neurology
/ Neurosciences
/ Parkinson Disease - genetics
/ Parkinson Disease - pathology
/ Pathology
/ Progressive supranuclear palsy
/ tau Proteins - genetics
/ α-Synuclein
2019
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
by
Sengupta, Medha
, Henderson, Michael X.
, Lee, Virginia M. Y.
, Trojanowski, John Q.
in
Aggregation
/ Alzheimer Disease - genetics
/ Alzheimer Disease - pathology
/ Alzheimer's disease
/ Amyloid β
/ Analysis
/ Antibodies
/ Biomedical and Life Sciences
/ Biomedicine
/ Brain - pathology
/ Clinical trials
/ Comorbidity
/ G2019S
/ Genetic aspects
/ Heterozygote
/ Humans
/ Leucine-rich repeat kinase 2
/ Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - genetics
/ Medical research
/ Mutation - genetics
/ Neurology
/ Neurosciences
/ Parkinson Disease - genetics
/ Parkinson Disease - pathology
/ Pathology
/ Progressive supranuclear palsy
/ tau Proteins - genetics
/ α-Synuclein
2019
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
by
Sengupta, Medha
, Henderson, Michael X.
, Lee, Virginia M. Y.
, Trojanowski, John Q.
in
Aggregation
/ Alzheimer Disease - genetics
/ Alzheimer Disease - pathology
/ Alzheimer's disease
/ Amyloid β
/ Analysis
/ Antibodies
/ Biomedical and Life Sciences
/ Biomedicine
/ Brain - pathology
/ Clinical trials
/ Comorbidity
/ G2019S
/ Genetic aspects
/ Heterozygote
/ Humans
/ Leucine-rich repeat kinase 2
/ Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - genetics
/ Medical research
/ Mutation - genetics
/ Neurology
/ Neurosciences
/ Parkinson Disease - genetics
/ Parkinson Disease - pathology
/ Pathology
/ Progressive supranuclear palsy
/ tau Proteins - genetics
/ α-Synuclein
2019
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Journal Article
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
2019
Request Book From Autostore
and Choose the Collection Method
Overview
Mutations in leucine-rich repeat kinase 2 (
LRRK2
) are the most common cause of familial Parkinson’s disease (PD). While the clinical presentation of
LRRK2
mutation carriers is similar to that of idiopathic PD (iPD) patients, the neuropathology of
LRRK2
PD is less clearly defined. Lewy bodies (LBs) composed of α-synuclein are a major feature of iPD, but are not present in all
LRRK2
PD cases. There is some evidence that tau may act as a neuropathological substrate in LB-negative
LRRK2
PD, but this has not been examined systematically. In the current study, we examined α-synuclein, tau, and amyloid β (Aβ) pathologies in 12
LRRK2
mutation carriers. We find that α-synuclein pathology is present in 63.6% of
LRRK2
mutation carriers, but tau pathology can be found in 100% of carriers and is abundant in 91% of carriers. We further use an antibody which selectively binds Alzheimer’s disease (AD)-type tau and use quantitative analysis of tau pathology to demonstrate that AD tau is the prominent type of tau present in
LRRK2
mutation carriers. Abundant Aβ pathology can also be found in
LRRK2
mutation carriers and is consistent with comorbid AD pathology. Finally, we assessed the association of neuropathology with clinical features in
LRRK2
mutation carriers and idiopathic individuals and find that
LRRK2
PD shares clinical and pathological features of idiopathic PD. The prevalence of AD-type tau pathology in
LRRK2
PD is an important consideration for understanding PD pathogenesis and refining clinical trial inclusion and progression criterion.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Alzheimer Disease - genetics
/ Alzheimer Disease - pathology
/ Analysis
/ Biomedical and Life Sciences
/ G2019S
/ Humans
/ Leucine-rich repeat kinase 2
/ Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - genetics
/ Parkinson Disease - genetics
/ Parkinson Disease - pathology
This website uses cookies to ensure you get the best experience on our website.